Abstract: This pharmaceutical containing collectively or separately as a combination an antibody having immunological reactivity with respect to CAPRIN 1 protein or a fragment of said antibody and an epidermal growth factor receptor (EGFR) inhibitor is useful for treating and/or preventing cancer.
| # | Name | Date |
|---|---|---|
| 1 | 202517022152-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [12-03-2025(online)].pdf | 2025-03-12 |
| 2 | 202517022152-STATEMENT OF UNDERTAKING (FORM 3) [12-03-2025(online)].pdf | 2025-03-12 |
| 4 | 202517022152-Sequence Listing in txt [12-03-2025(online)].txt | 2025-03-12 |
| 5 | 202517022152-Sequence Listing in PDF [12-03-2025(online)].pdf | 2025-03-12 |
| 6 | 202517022152-REQUEST FOR EXAMINATION (FORM-18) [12-03-2025(online)].pdf | 2025-03-12 |
| 7 | 202517022152-PROOF OF RIGHT [12-03-2025(online)].pdf | 2025-03-12 |
| 8 | 202517022152-POWER OF AUTHORITY [12-03-2025(online)].pdf | 2025-03-12 |
| 9 | 202517022152-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [12-03-2025(online)].pdf | 2025-03-12 |
| 10 | 202517022152-FORM 18 [12-03-2025(online)].pdf | 2025-03-12 |
| 11 | 202517022152-FORM 1 [12-03-2025(online)].pdf | 2025-03-12 |
| 12 | 202517022152-FIGURE OF ABSTRACT [12-03-2025(online)].pdf | 2025-03-12 |
| 13 | 202517022152-DRAWINGS [12-03-2025(online)].pdf | 2025-03-12 |
| 14 | 202517022152-DECLARATION OF INVENTORSHIP (FORM 5) [12-03-2025(online)].pdf | 2025-03-12 |
| 15 | 202517022152-COMPLETE SPECIFICATION [12-03-2025(online)].pdf | 2025-03-12 |
| 16 | 202517022152-certified copy of translation [13-03-2025(online)].pdf | 2025-03-13 |
| 17 | 202517022152-MARKED COPIES OF AMENDEMENTS [26-03-2025(online)].pdf | 2025-03-26 |
| 18 | 202517022152-FORM 13 [26-03-2025(online)].pdf | 2025-03-26 |
| 19 | 202517022152-AMMENDED DOCUMENTS [26-03-2025(online)].pdf | 2025-03-26 |
| 20 | 202517022152-FORM 3 [01-09-2025(online)].pdf | 2025-09-01 |